Correlation between Gut Microbiome and the Development of Diabetic Kidney Disease
DOI:
https://doi.org/10.37287/ijghr.v8i3.729Keywords:
diabetic kidney disease, dysbiosis, gut microbiome, inflammation, toddler, uremic toxinsAbstract
Diabetic kidney disease (DKD) is a major complication of diabetes mellitus characterized by progressive renal damage driven by metabolic, hemodynamic, and inflammatory mechanisms. Recent studies highlight the gut–kidney axis as a crucial pathway linking intestinal dysbiosis to DKD progression. Therefore, this study aims to investigate the association between gut microbiome alterations and the progression of DKD, as well as to explore potential mechanistic pathways linking microbial dysregulation to renal injury. A comprehensive literature review was conducted using PubMed, Scopus, Web of Science, ScienceDirect, and Google Scholar up to August 2025. Eligible studies included English-language human and experimental research evaluating the relationship between gut microbiota composition and DKD pathogenesis. From 241 retrieved articles, 22 studies met inclusion criteria. Most demonstrated significant gut dysbiosis in DKD, with decreased Faecalibacterium prausnitzii, Akkermansia muciniphila, and Butyricicoccus, and increased Escherichia-Shigella, Hungatella, and Enterococcus. Reduced short-chain fatty acid (SCFA) production and accumulation of uremic toxins—such as indoxyl sulfate, p-cresyl sulfate, and phenyl sulfate—were strongly associated with inflammation, fibrosis, and renal decline. The analysis was conducted through qualitative synthesis of study methodologies, microbial profiles, and biochemical markers to identify consistent patterns linking gut dysbiosis to DKD progression. These findings suggest that microbial imbalance and altered metabolite profiles play pivotal roles in DKD development. Interventions targeting the gut microbiota, including probiotics, prebiotics, and dietary fiber, may offer renoprotective benefits through restoration of SCFA-producing bacteria and reduction of uremic toxins. Gut dysbiosis in diabetic kidney disease (DKD) disrupts metabolic and immune balance by reducing beneficial short-chain fatty acid–producing bacteria and increasing pathogenic species, leading to inflammation, proteinuria, and progressive renal decline.
References
Afzaal, M., Saeed, F., Shah, Y. A., Hussain, M., Rabail, R., Socol, C. T., et al. (2022). Human gut microbiota in health and disease: Unveiling the relationship. Frontiers in Microbiology, 13, 999001. https://doi.org/10.3389/fmicb.2022.999001
Ahlawat, S., Asha, & Sharma, K. K. (2021). Gut-organ axis: A microbial outreach and networking. Letters in Applied Microbiology, 72(6), 636–668. https://doi.org/10.1111/lam.13333
Alam, S., Hasan, M. K., Neaz, S., Hussain, N., Hossain, M. F., & Rahman, T. (2021). Diabetes mellitus: Insights from epidemiology, biochemistry, risk factors, diagnosis, complications and comprehensive management. Diabetology, 2(2), 36–50. https://doi.org/10.3390/diabetology2020004
Allin, K. H., Tremaroli, V., Caesar, R., Jensen, B. A. H., Damgaard, M. T. F., Bahl, M. I., et al. (2018). Aberrant intestinal microbiota in individuals with prediabetes. Diabetologia, 61(4), 810–820. https://doi.org/10.1007/s00125-018-4550-1
American Diabetes Association Professional Practice Committee. (2024). 2. Diagnosis and classification of diabetes: Standards of care in diabetes—2024. Diabetes Care, 47(Suppl. 1), S20–S42. https://doi.org/10.2337/dc24-S002
Antar, S. A., Ashour, N. A., Sharaky, M., Khattab, M., Ashour, N. A., Zaid, R. T., Roh, E. J., Elkamhawy, A., & Al-Karmalawy, A. A. (2023). Diabetes mellitus: Classification, mediators, and complications; A gate to identify potential targets for the development of new effective treatments. Biomedicine & Pharmacotherapy, 168, 115734. https://doi.org/10.1016/j.biopha.2023.115734
Candela, M., Biagi, E., Soverini, M., et al. (2016). Modulation of gut microbiota dysbioses in type 2 diabetic patients by macrobiotic Ma-pi 2 diet. British Journal of Nutrition, 116, 80–93. https://doi.org/10.1017/S0007114516001045
Cani, P. D., Bibiloni, R., Knauf, C., Waget, A., Neyrinck, A. M., Delzenne, N. M., et al. (2008). Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet–induced obesity and diabetes in mice. Diabetes, 57(6), 1470–1481. https://doi.org/10.2337/db07-1403
Carías Domínguez, A. M., de Jesús Rosa Salazar, D., Stefanolo, J. P., Cruz Serrano, M. C., Casas, I. C., & Zuluaga Peña, J. R. (2024). Intestinal dysbiosis: Exploring definition, associated symptoms, and perspectives for a comprehensive understanding—A scoping review. Probiotics and Antimicrobial Proteins, 17(1), 440. https://pmc.ncbi.nlm.nih.gov/articles/PMC11832579/
Chelakkot, C., Ghim, J., & Ryu, S. H. (2018). Mechanisms regulating intestinal barrier integrity and its pathological implications. Experimental & Molecular Medicine, 50(8), 1–9. https://pubmed.ncbi.nlm.nih.gov/30115904/
Cheng, H.-T., Xu, X., Lim, P. S., & Hung, K.-Y. (2021). Worldwide epidemiology of diabetes-related end-stage renal disease, 2000–2015. Diabetes Care, 44(1), 89–97. https://doi.org/10.2337/dc20-1913
Cheng, T. H., Ma, M. C., Liao, M. T., Zheng, C. M., Lu, K. C., Liao, C. H., et al. (2020). Indoxyl sulfate, a tubular toxin, contributes to the development of chronic kidney disease. Toxins, 12(11), 684. https://www.mdpi.com/2072-6651/12/11/684
Cheng, X., Zhou, T., He, Y., Xie, Y., Xu, Y., & Huang, W. (2023). The role and mechanism of the gut microbiota in the development and treatment of diabetic kidney disease. Frontiers in Physiology, 14, 1166685. https://doi.org/10.3389/fphys.2023.1166685
Chong, S., Lin, M., Chong, D., Jensen, S., & Lau, N. S. (2025). A systematic review on gut microbiota in type 2 diabetes mellitus. Frontiers in Endocrinology, 15, 1486793. https://doi.org/10.3389/fendo.2024.1486793
de la Cuesta-Zuluaga, J., Mueller, N. T., Corrales-Agudelo, V., Velásquez-Mejía, E. P., Carmona, J. A., Abad, J. M., et al. (2016). Metformin is associated with higher relative abundance of mucin-degrading Akkermansia muciniphila and several short-chain fatty acid–producing microbiota in the gut. Diabetes Care, 40(1), 54–62. https://doi.org/10.2337/dc16-1324
DeFronzo, R. A., Reeves, W. B., & Awad, A. S. (2021). Pathophysiology of diabetic kidney disease: Impact of SGLT2 inhibitors. Nature Reviews Nephrology, 17, 319–334. https://doi.org/10.1038/s41581-021-00393-8
Desai, M. S., Seekatz, A. M., Koropatkin, N. M., Kamada, N., Hickey, C. A., Wolter, M., et al. (2016). A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility. Cell, 167(5), 1339–1353.e21. https://doi.org/10.1016/j.cell.2016.10.043
Gomaa, E. Z. (2020). Human gut microbiota/microbiome in health and diseases: A review. Antonie van Leeuwenhoek, 113(12), 2019–2040. https://pubmed.ncbi.nlm.nih.gov/33136284/
González-Correa, C., Moleón, J., Miñano, S., Robles-Vera, I., Toral, M., Barranco, A. M., et al. (2024). Differing contributions of the gut microbiota to the blood pressure lowering effects induced by first-line antihypertensive drugs. British Journal of Pharmacology, 181(18), 3420–3444. https://doi.org/10.1111/bph.16410
Gryp, T., Vanholder, R., Vaneechoutte, M., & Glorieux, G. (2017). p-Cresyl sulfate. Toxins, 9(2), 52. https://www.mdpi.com/2072-6651/9/2/52
Han, S., Chen, M., Cheng, P., Zhang, Z., Lu, Y., Xu, Y., et al. (2022). A systematic review and meta-analysis of gut microbiota in diabetic kidney disease: Comparisons with diabetes mellitus, non-diabetic kidney disease, and healthy individuals. Frontiers in Endocrinology, 13, 1018093. https://doi.org/10.3389/fendo.2022.1018093
He, J., Zhang, P., Shen, L., Niu, L., Tan, Y., Chen, L., et al. (2020). Short-chain fatty acids and their association with signalling pathways in inflammation, glucose and lipid metabolism. International Journal of Molecular Sciences, 21(17), 6356. https://www.mdpi.com/1422-0067/21/17/6356
Hobby, G. P., Karaduta, O., Dusio, G. F., Singh, M., Zybailov, B. L., & Arthur, J. M. (2019). Chronic kidney disease and the gut microbiome. American Journal of Physiology–Renal Physiology, 316(6), F1211–F1217. https://doi.org/10.1152/ajprenal.00298.2018
Hodgkinson, K., El Abbar, F., Dobranowski, P., Manoogian, J., Butcher, J., Figeys, D., et al. (2023). Butyrate’s role in human health and the current progress towards its clinical application to treat gastrointestinal disease. Clinical Nutrition, 42(2), 61–75. https://www.clinicalnutritionjournal.com/action/showFullText?pii=S0261561422003843
Hoogeveen, E. K. (2022). The epidemiology of diabetic kidney disease. Kidney and Dialysis, 2(3), 433–442. https://doi.org/10.3390/kidneydial2030038
Horowitz, A., Chanez-Paredes, S. D., Haest, X., & Turner, J. R. (2023). Paracellular permeability and tight junction regulation in gut health and disease. Nature Reviews Gastroenterology & Hepatology, 20(7), 417–432. https://www.nature.com/articles/s41575-023-00766-3
Hsu, B. G., Wang, C. H., Lin, Y. L., Lai, Y. H., & Tsai, J. P. (2022). Serum trimethylamine N-oxide level is associated with peripheral arterial stiffness in advanced non-dialysis chronic kidney disease patients. Toxins, 14(8), 539. https://pubmed.ncbi.nlm.nih.gov/36006188/
Huang, W., Guo, H. L., Deng, X., Zhu, T. T., Xiong, J. F., Xu, Y. H., et al. (2017). Short-chain fatty acids inhibit oxidative stress and inflammation in mesangial cells induced by high glucose and lipopolysaccharide. Experimental and Clinical Endocrinology & Diabetes, 125(2), 98–105. https://pubmed.ncbi.nlm.nih.gov/28049222/
Huang, Y., Xin, W., Xiong, J., Yao, M., Zhang, B., & Zhao, J. (2022). The intestinal microbiota and metabolites in the gut–kidney–heart axis of chronic kidney disease. Frontiers in Pharmacology, 13. https://pubmed.ncbi.nlm.nih.gov/35370631/
Hustrini, N. M., Susalit, E., & Rotmans, J. I. (2022). Prevalence and risk factors for chronic kidney disease in Indonesia: An analysis of the National Basic Health Survey 2018. Journal of Global Health, 12, 04074. https://doi.org/10.7189/jogh.12.04074
Kadatane, S. P., Satariano, M., Massey, M., Mongan, K., & Raina, R. (2023). The role of inflammation in CKD. Cells, 12(12), 1581. https://www.mdpi.com/2073-4409/12/12/1581
Kikuchi, K., Saigusa, D., Kanemitsu, Y., et al. (2019). Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease. Nature Communications, 10, 1835. https://doi.org/10.1038/s41467-019-09735-4
Koye, D. N., Magliano, D. J., Nelson, R. G., & Pavkov, M. E. (2018). The global epidemiology of diabetes and kidney disease. Advances in Chronic Kidney Disease, 25(2), 121–132. https://doi.org/10.1053/j.ackd.2017.10.011
Li, H.-B., Xu, M.-L., Xu, X.-D., Tang, Y.-Y., Jiang, H.-L., Li, L., et al. (2022). Faecalibacterium prausnitzii attenuates CKD via butyrate–renal GPR43 axis. Circulation Research, 131, e120–e134. https://doi.org/10.1161/CIRCRESAHA.122.320184
Li, Y. J., Chen, X., Kwan, T. K., Loh, Y. W., Singer, J., Liu, Y., et al. (2020). Dietary fiber protects against diabetic nephropathy through short-chain fatty acid–mediated activation of G protein–coupled receptors GPR43 and GPR109A. Journal of the American Society of Nephrology, 31(6), 1267–1282. https://journals.lww.com/jasn/fulltext/2020/06000/dietary_fiber_protects_against_diabetic.17.aspx
Lin, J. R., Wang, Z. T., Sun, J. J., et al. (2022). Gut microbiota and diabetic kidney diseases: Pathogenesis and therapeutic perspectives. World Journal of Diabetes, 13(4), 308–318. https://doi.org/10.4239/wjd.v13.i4.308
Liu, Y., Liu, Q., Zhang, C., Zhao, J., Zhang, H., Chen, W., & Zhai, Q. (2023). Strain-specific effects of Akkermansia muciniphila on the regulation of intestinal barrier. Food Science and Human Wellness, 12(5), 1526–1537. https://doi.org/10.1016/j.fshw.2023.02.022
Louis, P., & Flint, H. J. (2017). Formation of propionate and butyrate by the human colonic microbiota. Environmental Microbiology, 19(1), 29–41. https://pubmed.ncbi.nlm.nih.gov/27928878/
Lu, X., Ma, J., & Li, R. (2023). Alterations of gut microbiota in biopsy-proven diabetic nephropathy and a long history of diabetes without kidney damage. Scientific Reports, 13, 12150. https://doi.org/10.1038/s41598-023-39444-4
Martin-Gallausiaux, C., Marinelli, L., Blottière, H. M., Larraufie, P., & Lapaque, N. (2021). SCFA: Mechanisms and functional importance in the gut. Proceedings of the Nutrition Society, 80(1), 37–49. https://pubmed.ncbi.nlm.nih.gov/32238208/
Matoori, S. (2022). Diabetes and its complications. ACS Pharmacology & Translational Science, 5(8), 513–515. https://doi.org/10.1021/acsptsci.2c00122
Miranda, P. M., De Palma, G., Serkis, V., Lu, J., Louis-Auguste, M. P., McCarville, J. L., et al. (2018). High salt diet exacerbates colitis in mice by decreasing Lactobacillus levels and butyrate production. Microbiome, 6, 57. https://doi.org/10.1186/s40168-018-0433-4
Naaman, S. C., & Bakris, G. L. (2023). Diabetic nephropathy: Update on pillars of therapy slowing progression. Diabetes Care, 46(9), 1574–1586. https://doi.org/10.2337/dci23-0030
Nallu, A., Sharma, S., Ramezani, A., Muralidharan, J., & Raj, D. (2017). Gut microbiome in chronic kidney disease: Challenges and opportunities. Translational Research, 179, 24–37. https://www.translationalres.com/action/showFullText?pii=S1931524416300330
Niu, X., Wang, Y, Huang, L., Guo, P., Zhang, S., Sun, Y., et al. (2024). Effect of oral metformin on gut microbiota characteristics and metabolite fractions in normal-weight type 2 diabetic mellitus patients. Frontiers in Endocrinology, 15. https://www.frontiersin.org/articles/10.3389/fendo.2024.1397034
Nogal, A., Louca, P., Zhang, X., Wells, P. M., Steves, C. J., Spector, T. D., et al. (2021). Circulating levels of the short-chain fatty acid acetate mediate the effect of the gut microbiome on visceral fat. Frontiers in Microbiology, 12. https://www.frontiersin.org/articles/10.3389/fmicb.2021.711359
Ojo, O. A., Ibrahim, H. S., Rotimi, D. E., Ogunlakin, A. D., & Ojo, A. B. (2023). Diabetes mellitus: From molecular mechanism to pathophysiology and pharmacology. Medicine in Novel Technology and Devices, 19, 100247. https://doi.org/10.1016/j.medntd.2023.100247
Ong, K. L., et al. (2023). Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: A systematic analysis for the Global Burden of Disease Study 2021. The Lancet, 402(10397), 203–234.
Opdebeeck, B., D’Haese, P. C., & Verhulst, A. (2020). Molecular and cellular mechanisms that induce arterial calcification by indoxyl sulfate and p-cresyl sulfate. Toxins, 12(1), 58. https://pubmed.ncbi.nlm.nih.gov/31963891/
Pan, S., Zhao, D., Duan, S., & Chen, X. (2023). The role of gut-dependent molecule trimethylamine N-oxide as a novel target for the treatment of chronic kidney disease. International Urology and Nephrology, 55(7), 1747–1756. https://pubmed.ncbi.nlm.nih.gov/36797553/
Qian, N., Li, Y., Liu, Z., Chen, X., & Xie, J. (2022). Molecular mechanisms and therapeutic targets for diabetic kidney disease. International Review of Cell and Molecular Biology, 371, XX–XX. https://doi.org/10.1016/S0085-2538(22)00436-7
Remely, M., Hippe, B., Zanner, J., Aumueller, E., Brath, H., & Haslberger, A. G. (2016). Gut microbiota of obese, type 2 diabetic individuals is enriched in Faecalibacterium prausnitzii, Akkermansia muciniphila and Peptostreptococcus anaerobius after weight loss. Endocrine, Metabolic & Immune Disorders – Drug Targets, 16, 99–106. https://doi.org/10.2174/1871530316666160831093813
Rinninella, E., Raoul, P., Cintoni, M., et al. (2019). What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms, 7(1), 14. https://doi.org/10.3390/microorganisms7010014
Sharma, S., & Tripathi, P. (2019). Gut microbiome and type 2 diabetes: Where we are and where to go? Journal of Nutritional Biochemistry, 63, 101–108. https://doi.org/10.1016/j.jnutbio.2018.10.003
Smith, K. M., Francisco, S. G., Zhu, Y., LeRoith, T., Davis, M. L., Crott, J. W., et al. (2024). Dietary prevention of antibiotic-induced dysbiosis and mortality upon aging in mice. FASEB Journal, 38(23), e70241. https://doi.org/10.1096/fj.202402262R
Stavropoulou, E., Kantartzi, K., Tsigalou, C., Konstantinidis, T., Romanidou, G., Voidarou, C., et al. (2021). Focus on the gut–kidney axis in health and disease. Frontiers in Medicine, 7, 620102.
Sumida, K., & Kovesdy, C. P. (2019). The gut–kidney–heart axis in chronic kidney disease. Physiological International, 106(3), 195–206. https://akjournals.com/view/journals/2060/106/3/article-p195.xml
Sumida, K., Molnar, M. Z., Potukuchi, P. K., Thomas, F., Lu, J. L., Matsushita, K., et al. (2017). Constipation and incident CKD. Journal of the American Society of Nephrology, 28(4), 1248–1258. https://pubmed.ncbi.nlm.nih.gov/28122944/
Sun, H., Saeedi, P., Karuranga, S., et al. (2022). IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Research and Clinical Practice, 183, 109119. https://doi.org/10.1016/j.diabres.2021.109119
Tang, W. H. W., Wang, Z., Kennedy, D. J., Wu, Y., Buffa, J. A., Agatisa-Boyle, B., et al. (2014). Gut microbiota–dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circulation Research, 116(3), 448–455. https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.116.305360
Tang, X., Chen, X., Ferrari, M., Walvoort, M. T. C., & de Vos, P. (2024). Gut epithelial barrier function is impacted by hyperglycemia and secondary bile acids in vitro: Possible rescuing effects of specific pectins. Molecular Nutrition & Food Research, 68(11), 2300910. https://doi.org/10.1002/mnfr.202300910
Tao, S., Li, L., Li, L., et al. (2019). Understanding the gut–kidney axis among biopsy-proven diabetic nephropathy, type 2 diabetes mellitus and healthy controls: An analysis of the gut microbiota composition. Acta Diabetologica, 56, 581–592. https://doi.org/10.1007/s00592-019-01316-7
Thaiss, C. A., Levy, M., Grosheva, I., Zheng, D., Soffer, E., Blacher, E., et al. (2018). Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection. Science, 359(6382), 1376–1383. https://doi.org/10.1126/science.aar3318
Tourountzis, T., Lioulios, G., Fylaktou, A, Moysidou, E., Papagianni, A., & Stangou, M. (2022). Microbiome in chronic kidney disease. Life, 12(10), 1513. https://pmc.ncbi.nlm.nih.gov/articles/PMC9604691/
Tsuji, K., Uchida, N., Nakanoh, H., Fukushima, K., Haraguchi, S., Kitamura, S., et al. (2024). The gut–kidney axis in chronic kidney diseases. Diagnostics, 15(1), 21. https://www.mdpi.com/2075-4418/15/1/21
Ullah, H., Arbab, S., Tian, Y., Liu, C. Q., Chen, Y., Qijie, L., et al. (2023). The gut microbiota–brain axis in neurological disorder. Frontiers in Neuroscience, 17. https://pubmed.ncbi.nlm.nih.gov/37600019/
Wilck, N., Matus, M. G., Kearney, S. M., Olesen, S. W., Forslund, K., Bartolomaeus, H., et al. (2017). Salt-responsive gut commensal modulates TH17 axis and disease. Nature, 551(7682), 585–589. http://dx.doi.org/10.1038/nature24628
Wu, D., Tang, X., Ding, L., Cui, J., Wang, P., Du, X., et al. (2019). Candesartan attenuates hypertension-associated pathophysiological alterations in the gut. Biomedicine & Pharmacotherapy, 116, 109040. https://www.sciencedirect.com/science/article/pii/S0753332219309035
Wu, H., Esteve, E., Tremaroli, V., Khan, M. T., Caesar, R., Mannerås-Holm, L., et al. (2017). Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nature Medicine, 23(7), 850–858. https://doi.org/10.1038/nm.4345
Wu, H., Tremaroli, V., Schmidt, C., Lundqvist, A., Olsson, L. M., Krämer, M., et al. (2020). The gut microbiota in prediabetes and diabetes: A population-based cross-sectional study. Cell Metabolism, 32(3), 379–390.e3. https://doi.org/10.1016/j.cmet.2020.06.011
Wu, I. W., Lin, C. Y., Chang, L. C., et al. (2020). Gut microbiota as diagnostic tools for mirroring disease progression and circulating nephrotoxin levels in chronic kidney disease: Discovery and validation study. International Journal of Biological Sciences, 16(3), 420–434. https://doi.org/10.7150/ijbs.37421
Wu, J., Wang, K., Wang, X., Pang, Y., & Jiang, C. (2021). The role of the gut microbiome and its metabolites in metabolic diseases. Protein & Cell, 12(5), 360–373. https://doi.org/10.1007/s13238-020-00814-7
Xiong, L., Diwakarla, S., Chatzis, R., Artaiz, O., Macowan, M., Zhang, S., et al. (2025). Acute exposure to high-fat diet impairs ILC3 functions and gut homeostasis. Immunity, 58(5), 1185–1200.e8. https://doi.org/10.1016/j.immuni.2025.03.017
Yokoo, K., Yamamoto, Y., & Suzuki, T. (2021). Ammonia impairs tight junction barriers by inducing mitochondrial dysfunction in Caco-2 cells. FASEB Journal, 35(11), e21968. https://pubmed.ncbi.nlm.nih.gov/34597422/
Zafar, H., & Saier, M. H. (2021). Gut Bacteroides species in health and disease. Gut Microbes, 13(1), 1–20. https://doi.org/10.1080/19490976.2020.1848158
Zhang, L., Wang, Z., Zhang, X., Zhao, L., Chu, J., Li, H., et al. (2022). Alterations of the gut microbiota in patients with diabetic nephropathy. Microbiology Spectrum, 10(4), e00324-22.
Zhang, X., Gaballa, M. M. S., Hasan, A. A., Liu, Y., Hocher, J.-G., Chen, X., et al. (2025). Effects of high salt intake on glucose metabolism, liver function, and the microbiome in rats: Influence of ACE inhibitors and angiotensin II receptor blockers. American Journal of Physiology–Cell Physiology, 328(4), C1366–C1382. https://doi.org/10.1152/ajpcell.01036.2024
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Indonesian Journal of Global Health Research
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
